# Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

> **NCT02937701** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 558 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** ABP 710
- **BIOLOGICAL:** Infliximab

## Key facts

- **NCT ID:** NCT02937701
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-10
- **Primary completion:** 2018-04-16
- **Final completion:** 2018-08-13
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937701, "Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02937701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*